Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07095452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07095452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 8, 2026
Completion date
May 31, 2041
Enrollment
680 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma